| 发明名称 |
Methods for the identification and treatment of patients sensitive to anti IGF-1R inhibition therapy |
| 摘要 |
The present invention relates to methods for treating a dalotuzumab responsive cancer, in a patient, comprising determining the expression level of liver kinase B1 (LKB1), in a cancer cell from the patient, and when said expression is determined to be lower than that of a control cell; administering, to said patient, a therapeutically effective amount of dalotuzumab. The invention also relates to methods for assessing neoplastic cells, selecting patients, selecting therapies as well as diagnostic methods. |
| 申请公布号 |
US9110082(B2) |
申请公布日期 |
2015.08.18 |
| 申请号 |
US201013512061 |
申请日期 |
2010.11.22 |
| 申请人 |
MERCK SHARP & DOHME CORP. |
发明人 |
Sathyanarayanan Sriram;Winter Christopher;Xu Youyuan |
| 分类号 |
G01N33/68;A61N5/02;A61N5/10;C12Q1/68;G01N33/50;A61K39/395;A61K45/06;A61N5/06 |
主分类号 |
G01N33/68 |
| 代理机构 |
|
代理人 |
|
| 主权项 |
1. A method for treating a dalotuzumab responsive cancer, in a patient, comprising: (a) determining the expression level of liver kinase B1 (LKB1), in a cancer cell from the patient, and when said expression is determined to be lower than that of a control cell; (b) administering, to said patient, a therapeutically effective amount of dalotuzumab. |
| 地址 |
Rahway NJ US |
